Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2019

Jan 30, 2020

SELL
$2.25 - $5.8 $144 - $371
-64 Closed
0 $0
Q3 2018

Nov 09, 2018

SELL
$8.6 - $11.26 $903 - $1,182
-105 Reduced 62.13%
64 $1,000
Q2 2018

Jul 30, 2018

BUY
$9.52 - $12.15 $1,608 - $2,053
169 New
169 $2,000

Others Institutions Holding IMGN

About ImmunoGen, Inc.


  • Ticker IMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 220,712,992
  • Description
  • ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...
More about IMGN
Track This Portfolio

Track Trustcore Financial Services, LLC Portfolio

Follow Trustcore Financial Services, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Trustcore Financial Services, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Trustcore Financial Services, LLC with notifications on news.